TYRA BIOSCIENCES, INC.
- Market cap
- 1.40B
- P/E (TTM)i
- -8.53
- P/Bi
- 3.96
- EPSi
- -2.01
- Div yieldi
- 0.00%
- 52W posi
- 26%
Anonymous reader poll. Unscientific, not investment advice.
About TYRA BIOSCIENCES, INC.
Tyra Biosciences, Inc. is a precision oncology company focused on developing purpose-built therapies to overcome tumor resistance and improve outcomes for patients with cancer. Its proprietary in-house discovery platform, SN?P, enables the rapid and precise refinement of structural design through iterative molecular SN?Pshots that help predict genetic alterations most likely to cause acquired resistance to existing therapies. TYRA is developing a pipeline of selective inhibitors of the Fibroblast Growth Factor Receptor (FGFR) family members, which are altered in approximately 7% of all cancers. The company was founded by Daniel Bensen and Todd Harris on August 2, 2018 and is headquartered in Carlsbad, CA.
- Founded
- 2018
- CEO
- Dr. Todd Harris, PhD
- Employees
- 87
- Headquarters
- Carlsbad, California, United States of America
- Fiscal year end
- 12-31
- Website
- tyra.bio
Company profile
- Exchange
- US
- Symbol
- TYRA
- Market-cap rank
- #3032
- Listing date
- 2021-09-15
- Market cap
- 1.40B
- Float cap
- 814.03M
- Shares out
- 68.76M
- Float shares
- 39.92M
Sectors & themes
Quote time 2026-10-07 19:54:59 · For reference only, not investment advice and not tailored to your situation.